Bevenopran
Alternative Names: ADL5945; CB-5945; MK-2402; OpRA IIILatest Information Update: 05 Nov 2023
At a glance
- Originator Eli Lilly and Company
- Developer Merck & Co
- Class Amides; Laxatives; Phenyl ethers; Pyrans; Pyrazines; Small molecules
- Mechanism of Action Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Constipation
Most Recent Events
- 07 May 2015 Discontinued - Phase-III for Constipation in USA, Canada (PO)
- 07 May 2015 Cubist Pharmaceuticals suspends a phase I trial for Constipation in USA (PO) (NCT02508740)
- 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co